Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
Nathan M Denlinger, Narendranath Epperla, Basem M William Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center (OSUCCC-James), The Ohio State University, Columbus, OH, USA Abstract: Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which ar...
Main Authors: | Denlinger NM, Epperla N, William BM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-03-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/management-of-relapsedrefractory-marginal-zone-lymphoma-focus-on-ibrut-peer-reviewed-article-CMAR |
Similar Items
-
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
by: Brendan P. Hodkinson, et al.
Published: (2021-01-01) -
Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
by: Young‐Woo Jeon, et al.
Published: (2019-11-01) -
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
by: Anna Mair, et al.
Published: (2021-09-01) -
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
by: Michael Wang, et al.
Published: (2017-11-01) -
Indolent B-Cell Lymphoid Malignancy in the Spleen of a Man Who Handled Benzene: Splenic Marginal Zone Lymphoma
by: Jihye Lee, et al.
Published: (2017-09-01)